These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33268022)

  • 21. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age.
    Smith E; Rothschild AJ; Heo M; Peasley-Miklus C; Caswell M; Papademetriou E; Flint AJ; Mulsant BH; Meyers BS;
    Int Clin Psychopharmacol; 2008 May; 23(3):130-7. PubMed ID: 18408527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.
    Blumberger DM; Mulsant BH; Emeremni C; Houck P; Andreescu C; Mazumdar S; Whyte E; Rothschild AJ; Flint AJ; Meyers BS
    J Psychiatr Res; 2011 Jul; 45(7):896-901. PubMed ID: 21300377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.
    Davies SJ; Mulsant BH; Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Kirshner MM; Sorisio D; Pollock BG; Bies RR;
    Hum Psychopharmacol; 2016 May; 31(3):252-5. PubMed ID: 27060853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.
    Bingham KS; Whyte EM; Meyers BS; Mulsant BH; Rothschild AJ; Banerjee S; Flint AJ;
    Am J Geriatr Psychiatry; 2015 Dec; 23(12):1270-1275. PubMed ID: 26560512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
    Davies SJ; Mulsant BH; Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Kirshner MM; Sorisio D; Pollock BG; Bies RR
    Clin Pharmacokinet; 2015 Nov; 54(11):1161-8. PubMed ID: 25971243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features.
    Kim HK; Voineskos AN; Neufeld NH; Alexopoulos GS; Bingham KS; Flint AJ; Marino P; Rothschild AJ; Whyte EM; Mulsant BH
    Mol Psychiatry; 2024 Aug; 29(8):2459-2466. PubMed ID: 38503927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
    Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
    Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.
    Karagianis J; Grossman L; Landry J; Reed VA; de Haan L; Maguire GA; Hoffmann VP; Milev R
    Schizophr Res; 2009 Aug; 113(1):41-8. PubMed ID: 19535229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mifepristone treatment of olanzapine-induced weight gain in healthy men.
    Gross C; Blasey CM; Roe RL; Allen K; Block TS; Belanoff JK
    Adv Ther; 2009 Oct; 26(10):959-69. PubMed ID: 19888560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
    Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
    J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
    J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prescription of olanzapine in children and adolescent psychiatric patients].
    Frémaux T; Reymann JM; Chevreuil C; Bentué-Ferrer D
    Encephale; 2007; 33(2):188-96. PubMed ID: 17675914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.
    Detke HC; DelBello MP; Landry J; Usher RW
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):217-24. PubMed ID: 25721187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.